Searched for
BIOTECH FIRM
Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...- US says BYD, Baidu and Alibaba are aiding China's militaryAmerica has released a new list of Chinese companies it believes support Beijing's military. Major firms like Alibaba, Baidu, and BYD are i...
- US says BYD, Baidu and Alibaba and other tech giants are aiding China's militaryThe U.S. has updated its list of Chinese companies aiding Beijing's military, adding tech giants like Alibaba and Baidu, alongside chipmake...
- Samsung minority union challenges bonus deal in courtA labour union representing several thousand Samsung Electronics employees asked a court on Tuesday to nullify a bonus agreement between th...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- H-1B chill sets in; Flipkart doubles down on ShopsyUS demand for H-1B visas has slumped to a seven-year low amid steeper costs and Trump-era policy shifts. This and more in today’s ETtech To...
- VCs eye deeptech fund launches to leverage RDI capitalSector-agnostic VC firms Kalaari Capital and Blue Ashva Capital are among those exploring new deeptech-focussed vehicles amid rising invest...
- Modal Labs valued at $4.65 billion as AI coding takes offAI startups have been whipped by two shifts this year: the surge in AI coding and the increasing scarcity of computing power. Modal Labs is...
- Shastra VC launches $100 million fund to back deeptech, AI startupsThe Bengaluru-based firm said the new vehicle will invest between $500,000 and $3 million in IP-led firms across these sectors. The launch ...
- Why SpaceX's mega IPO may not signal a broader rebound in listingsSpaceX's huge IPO is set to capture global attention. However, experts believe this event may not reflect the true health of the broader IP...
- Global Market: Hong Kong IPO boom draws rising interest from overseas companiesHong Kong's stock market is seeing more foreign companies file for listings. Firms from countries like Indonesia and South Korea are explor...
- Want to jump into the 'China is back' rally? Tread carefullyInvestors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...
- Flipkart puts IPO on ice; Rapido's $240 million raiseFlipkart has hit pause on its IPO in a jittery market. This and more in today's ETtech Top 5.
- US CEOs seek China business gains from Trump-Xi summitAmerican business leaders are heading to China for a summit with President Xi Jinping. They aim to resolve ongoing business challenges and ...
- Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapyLast October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of the therap...
- Global Markets | Australian shares slide as banks, CSL drag; US‑Iran tensions hit risk appetiteBiotech darling CSL tumbled 16% after it slashed its full-year 2026 outlook and flagged a $5 billion impairment. The stock dragged the hea...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
Load More
